BRCA1 and ovarian carcinoma: The model’s ability to distinguish between BRCA1/2 mutation carriers and non-carriers might, in the context of a positive family history of breast and/or ovarian cancer, serve as an indicator to consider formal genetic risk assessment in persons who have not been previously tested.